医药行业周报：益普生FIC小分子获FDA批准，用于治疗PBC

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding the CSI 300 Index by more than 5% in the next six months [4]. Core Viewpoints - The pharmaceutical sector showed a performance increase of +1.01% on June 11, 2024, outperforming the CSI 300 Index by 1.88 percentage points, ranking fourth among 31 sub-industries in the Shenwan classification [3]. - Notable sub-industry performances include Other Biological Products (+1.98%), Vaccines (+1.58%), and Blood Products (+1.52%), while Pharmaceutical Distribution (-0.41%) and Offline Pharmacies (+0.05%) lagged behind [3]. - The report highlights the FDA's accelerated approval of Iqirvo (Elafibranor) for treating Primary Biliary Cholangitis (PBC), marking it as the first new drug approved for this rare liver disease in nearly a decade [3]. Summary by Sections Market Performance - The pharmaceutical sector's performance on June 11, 2024, was +1.01%, outperforming the CSI 300 Index by 1.88 percentage points [3]. - The report notes the top three gainers in individual stocks: Dize Pharmaceutical (+10.37%), Han Commercial Group (+9.95%), and Haitai New Light (+8.81%) [3]. Sub-industry Ratings - Chemical Pharmaceuticals and Traditional Chinese Medicine have no rating, while Biopharmaceuticals II is rated as Neutral [3]. Company News - Yipusheng announced the FDA's approval for Iqirvo in combination with Ursodeoxycholic Acid (UDCA) for adults with insufficient response to UDCA, or as monotherapy for those intolerant to UDCA [3]. - Weili Medical's product received FDA pre-registration for routine urination or postoperative drainage [3].